Clinical Trial: Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures

U.S., April 2 -- ClinicalTrials.gov registry received information related to the study (NCT07505004) titled 'Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures' on March 26.

Brief Summary: A multicenter, double-blind, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of vormatrigine in adults with focal seizures (POWER2)

Study Start Date: Jan. 29

Study Type: INTERVENTIONAL

Condition: Focal Epilepsy

Intervention: DRUG: 40 mg/day vormatrogine for 12 weeks

Once daily oral

DRUG: 30 mg/day vormatrogine for 12 weeks

Once daily oral

DRUG: 20 mg/day vormatrogine for 12 weeks

Once daily oral

DRUG: Placebo

Once daily oral

Recruitment S...